MedTrace Logo

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

NCT00732420 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2017-11-13

No results posted yet for this study

Summary

To determined what dose of topotecan can be safely given with daily pazopanib.

Conditions

Interventions

DRUG

topotecan

Topoisomerase I inhibition.

DRUG

pazopanib

Tyrosine kinase inhibitor

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-24
Primary Completion
2013-06-12
Completion
2013-06-12

Countries

  • United States
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00732420 on ClinicalTrials.gov